Our previous studies demonstrated that adenovirus-mediated overexpression of melanoma differentiation-associated gene-7 (Admda7) leads to rapid induction of double-stranded RNA-dependent protein kinase (PKR) and activation of its downstream targets, resulting in apoptosis induction in human lung cancer cells. Here, we report that Ad-mda7 and the benzoquinone ansamycin geldanamycin (GA) interact in a highly synergistic manner to induce cell death in human lung cancer cells. Co-administration of Ad-mda7 and GA did not modify expression of MDA-7, and was not associated with further PKR induction and activation; instead the enhanced cytotoxicity of this combination was associated with inactivation of AKT by GA. By surface staining using anti-E-cadherin monoclonal antibody and flow cytometry, we found that treatment with the combination of Ad-mda7 and GA increased E-cadherin levels in these cancer cells. Ad-mda7 and GA cotreatment also inhibited lung cancer cell motility by increasing the b-catenin/E-cadherin association. Moreover, combination of GA derivative 17-allyl-amino, 17-demethoxygeldanamycin (17AAG), with Ad-mda7 resulted in enhancement of cell death in A549 and H460 human lung cancer cells.
Introduction
Melanoma differentiation-associated gene-7 (mda-7) was identified by a subtraction hybridization approach in human HO-1 melanoma cells treated with a combination of recombinant human fibroblast interferon-b and the protein kinase C activator mezerein.
1 Adenoviral overexpression of MDA-7 leads to tumor-selective growth suppression and apoptosis induction in various tumor types including colorectal, 2 breast, 3 prostate 4 and lung carcinoma. 5 We have demonstrated that adenovirusmediated overexpression of mda-7 leads to rapid induction of double-stranded (ds) RNA-dependent protein kinase (PKR), with subsequent phosphorylation of eIF-2a and other PKR target substrates and of induction apoptosis in human lung cancer cells. 6 PKR is involved in the regulation of apoptosis, cell-proliferation, signal transduction and differentiation. [7] [8] [9] It has been shown that PKR is regulated by the heat shock protein 90 (Hsp90) molecular chaperone complex. 10 Hsp90 and its cochaperone p23 bind to PKR through its N-terminal ds RNA-binding region as well as through its kinase domain. 10 Both dsRNA and geldanamycin (hereafter referred to as GA) induce the rapid dissociation of Hsp90 and p23 from mature PKR, activating PKR both in vivo and in vitro. 10 17-allyl-amino-geldanamycin (17AAG) is a derivative of the GA that is currently undergoing clinical development in humans. 11 We hypothesized that GA (or 17AAG) would activate PKR or block AKT and further enhance the antitumor efficacy of Ad-mda7. Here, we report that Ad-mda7 and the benzoquinone ansamycin geldanamycin (GA) interact in a highly synergistic manner to induce cell death through inhibition of p-AKT in human lung cancer cells.
Materials and methods
Cell lines and reagents A549 and H460 human lung cancer cell lines were obtained from the American Type Culture Collection. All cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 10 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (Life Technologies Inc., Grand Island, NY, USA) in a 5% CO 2 atmosphere at 371C. GA was obtained from Calbiochem (San Diego, CA, USA). 17AAG was kindly provided by Dr Nguyen Dao (National Cancer Institute, Bethesda, MD, USA). 17AAG was formulated in dimethyl sulfoxide (DMSO; Sigma Chemical Co., St Louis, MO, USA) as 10-mM stock solutions, and stored at À201C. Final working solutions were diluted in medium to contain o0.01% of DMSO. All experiments using this compound were performed under subdued lighting conditions.
Adenovirus production
Construction of the Ad-mda7, Ad-LacZ and Ad-luc vectors have been reported previously. 6 The transduction efficiencies of adenoviral vectors in A549 and H460 cancer cell lines were determined by infecting cells with Ad-LacZ and then quantifying the titers needed to transduce at least 70% of the cells.
Flow cytometry analysis
We measured apoptotic cells by propidium iodide staining and FACS analysis. Cells were harvested; pelleted by centrifugation; resuspended in PBS containing 50 mg/ml propidium iodide, 0.1% Triton X-100 and 0.1% sodium citrate; and subjected to vortexing before FACS analysis (Becton-Dickenson FACScan, Mountain View, CA, USA; FL-3 channel).
Western blot analysis
At 48 h after transfection, the cell extracts were prepared and immunoblot assays performed as described elsewhere. 6 The following antibodies were used: PKR (K-17), HSP90, b-catenin, E-cadherin, Raf-1 and b-actin antibodies were bought from Santa Cruz Biotechnology (Santa Cruz, CA, USA); phospho-PKR (pT451) and phospho-eIF-2a (pS51) antibodies were purchased from BioSource International; Akt and phospho-Akt (Ser473) were bought from Cell Signaling Technologies, Beverly, MA, USA). The polyclonal or monoclonal antibody to MDA-7 was obtained from Introgen Therapeutics Inc. (Houston, TX, USA).
Immunofluorescence analysis A549 cells (5 Â 10 4 cells/well) were grown on chamber slides until 70% confluence and then treated with Ad-luc, Ad-mda7, GA, Ad-mda7 plus GA or Ad-luc plus GA. After 48 h, cells were washed with PBS and fixed with freshly made 4% paraformaldehyde/PBS for 15 min. Cells were then permeabilized for 20 min at 41C with 0.2% Triton X-100 and blocked 1 h with 1% normal goat serum. Rabbit polyclonal anti-b-catenin were incubated overnight at 41C and developed with rhodamine secondary antibodies for 30 min at 371C. Cells were then visualized under the fluorescence microscope (Olympus BX50 fluorescent microscope). 12 Immunoprecipitation analysis Cells were treated with PBS, Ad-mda7, Ad-mda7 plus GA or GA alone for 48 h, and then subjected to lysis in RIPA buffer (1 Â PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS). Cell lysates (500 ml (500 mg)) were incubated with primary antibody overnight at 41C. Protein A/G agarose was added to the mix, which was incubated for a further 4 h. Beads were pelleted by centrifugation at 2500 r.p.m. for 5 min at 41C and washed four times with 1 ml of RIPA buffer. After the last wash, 50 ml of 1 Â SDS-polyacrylamide gel electrophoresis sample buffer was added to the beads. This preparation was subjected to vortexing and then boiled for 5 min. It was centrifuged at 2500 r.p.m. for 1 min before the supernatants were loaded on gels.
Motility assay Medium (0.7 ml) was added to each well of a 24-well plate (Costar). Cell-culture inserts (8 mm pore size, Falcon 3097, Fisher) were placed into each well. A549 and H460 cells were adjusted to a concentration of 5 Â 10 5 cells/ml, and 500 ml of cells were placed into each insert. Cells were incubated for 36 h with PBS, Ad-luc, Ad-mda7, GA, Ad-mda7 plus GA or Ad-luc plus GA. After 36 h, the numbers of cells adherent to the bottoms of the wells were counted. Motility is expressed as a percentage of the number of cells in drug-free wells adhering to the well after 36 h.
Statistical analysis
The data reported represent the mean of three or more independent experiments and the bars show the s.d. ANOVA and two-tailed Student's t-test were used for statistical analysis of multiple groups and pair-wise comparison, respectively, with Po0.05 considered significant.
Results

GA enhances adenoviral mda-7-mediated cell killing in human lung cancer cells
We first investigated whether GA could induce cell death in human lung cancer A549 and H460 cells. Flow cytometric analysis was performed in the A549 and H460 cell lines 48 h following exposure to different doses of GA. Treatment of lung cancer cells with GA resulted in does-dependent cell death in both cell lines ( Figure 1a ). We next examined the effects of treatment with Ad-mda7 alone and in combination with 50 or 150 nM doses of GA, for 48 h in both A549 and H460 cell lines. Flow cytometric analysis showed that Ad-mda7 alone resulted in 15 and 12% cell death in A549 and H460 cells, respectively. GA alone at a dose 50 nM resulted in 6.3 and 5.7% cell death in A549 and H460 cells, respectively, at 48 h while after the same time period GA alone at a dose of 150 nM resulted in 23.6 and 21% cell death in A549 and H460 cells, respectively. The combination of GA at the two doses and Ad-mda7 resulted in a substantial enhancement of cell death in both A549 (32.3 and 51%) (Po0.05) and H460 (27.7 and 43.5%) (Po0.05) lung cancer cells (Figure 1b ). No such enhancement of cell death was observed after treatment of these cells with a combination of GA and adenoviral luciferase (Ad-luc) ( Figure 1b ).
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Treatment with a combination of Ad-mda7 and GA does not increase expression of PKR We reported previously that Ad-mda7 induces and activates PKR, which leads to phosphorylation of eIF2a and the induction of cell death in lung cancer cells. 6 We therefore tested whether treatment with a combination of Ad-mda7 and GA increased the expression levels and phosphorylation status of PKR. A549 and H460 cells treated with Ad-mda7 displayed an increase in the PKR and phosphorylated PKR, whereas treatment with phosphate-buffered saline, (PBS), GA, or Ad-luc did not increase expression of PKR or its phosphorylation status. The combination of Ad-mda7 and GA did not enhance expression of PKR or its phosphorylation status in either A549 (Figure 2a ) or H460 (Figure 2b ) cells. Rather, treatment of these cancer cells with GA caused degradation of AKT and p-AKT, Raf targets that require Hsp90 for conformational maturation (Figure 2a and b) . Interestingly, Ad-mda7 degraded AKT but at the same time increased phosphorylation of AKT (p-AKT) in both A549 and H460 cells. Ad-mda7 and GA cotreatment significantly degraded phosphorylated AKT (p-AKT) in these cancer cells (Figure 2a and b) . These results suggest that inhibition of p-AKT may attributable in part to a synergistic effect of Ad-mda7 and GA.
Ad-mda7 and GA combination upregulates surface E-cadherin and increases of b-catenin/E-cadherin association in lung cancer cells A previous report showed that Ad-mda7 could upregulate E-cadherin in human lung cancer cells. 3 We therefore investigated whether the combination of Ad-mda7 and GA could enhance upregulation of E-cadherin in human lung cancer cells. As shown in Figure 3a , Ad-mda7 or GA alone could increase E-cadherin levels in A549 and H460 cells, as detected by surface staining using anti-E-cadherin monoclonal antibody and flow cytometry. The combination of Ad-mda7 and GA (50 nM) increased E-cadherin levels in these cells significantly more than treatment with PBS, Ad-luc, Ad-mda7, GA alone or Ad-luc plus GA (Po0.05). Figure 3b shows that Ad-mda7 or GA alone can increase b-catenin levels in A549 cells (as detected by immunofluorescence staining). Combination of Ad-mda7 
The previous study also demonstrated that GA could stimulate tyrosine dephosphorylation of b-catenin and increase b-catenin/E-cadherin association, resulting in substantially decreased cell motility. 13 We therefore investigated whether treatment with a combination of Ad-mda7 and GA could increase b-catenin/E-cadherin association. Cells treated with PBS, Ad-mda7 alone, GA alone or combinations of Ad-mda7 and GA were first immunoprecipitated with anti-E-cadherin antibody and then immunoblotted with a b-catenin-specific antibody. Figure 3c shows that the amount of b-catenin coimmunoprecipitated with E-cadherin has dramatically higher in both A549 and H460 cells treated with the combination of Ad-mda7 and GA than in cells treated with PBS, Ad-mda7 alone or GA alone. The same level of E-cadherin also could be detected when the immunoprecipitates were immunoblotted with anti-E-cadherin antibody in both cell lines (Figure 3c) .
As the abundance of membrane-associated b-catenin-E-cadherin complexes is inversely related to cell motility, we sought to determine whether the combination of Ad-mda7 and GA could reduce the motility of A549 and H460 cells in vitro. When added to a 36-h in vitro motility assay, Ad-mda7 or GA (50 nM) alone reduced motility in both cell lines without affecting cell viability as assessed by Trypan blue staining (Figure 3d ). Co-treatment with Ad-mda7 and GA resulted in substantially decreased motility of both A549 and H460 cells (Figure 3d) . Motility was not decreased in cells co-treated with Ad-luc and GA (Figure 3d) .
We next investigated whether GA analogue 17AAG could have same effect as GA on human lung cancer cells. Flow cytometric analysis was performed on the A549 and H460 cell lines 48 h following exposure to two different doses of 17AAG. Figure 4 shows that treatment of lung cancer cells with 17AAG or Ad-mda7 alone resulted in high percentages of cell death in both cell lines. Treatment with a combination of 17AAG and Ad-mda7 resulted in higher rates of cell death than the combination of Ad-luc and 17AAG in both A549 and H460 cells (Figure 4 ).
Discussion
Ad-mda7 produces a novel tumor suppressor gene, MDA-7, that is present in both intracellular and secreted forms after adenoviral transduction. 14 The intracellular form induces a variety of molecular pathways leading to apoptosis in and regression of locally injected tumors.
14 Moreover, intratumoral injection of Ad-mda7 leads to secretion of a soluble MDA-7 protein that has been shown in animal models to circulate in the vasculature to distant sites and induce tumor regression through antiangiogenetic and immunomodulatory effects. 15 Our previous studies demonstrated that adenovirus-mediated overexpression of MDA-7 leads to rapid induction of PKR, with subsequent phosphorylation of eIF-2a and other PKR target substrates, and apoptosis induction in human lung cancer cells. 6 The unique ability of Ad-mda7 to upregulate PKR allows the potential for combination therapies with drugs that enhance PKR activity to overcome tumor resistance and increase antitumor activity. PKR is an interferon-induced and ds RNA-activated protein kinase. Although best characterized for its function in mediating the antiviral and antiproliferative effects of interferon, PKR is implicated in transcriptional regulation, cell differentiation, signal transduction and tumor suppression. 16 PKR also has been shown to bind to Hsp90 and its co-chaperone p23. Hsp90 is a chaperone required for the refolding of proteins in cells exposed to environmental stress and for the conformational maturation of several key regulatory proteins. 17 GA and 17AAG can bind specifically to the ATP-binding site in the NH 2 -terminal portion of Hsp90 and inhibit its function. Inhibition of Hsp90 function leads to degradation of its client proteins, including steroid receptors, HER2, and the Raf, PDK1, AKT and cdk4 kinases. 18 We hypothesize that GA or 17AAG, as HSP90 inhibitor would be expected to increase the Ad-mda7-mediated cell killing in lung cancer cells. To test this possibility, we have examined interactions between Ad-mda7 and GA in human lung cancer cells, emphasizing effects on induction of cell death. 
Enhancement of adenovirus-mediated MDA-7 cell killing A Pataer et al
Flow cytometric analysis showed that treatment with Ad-mda7 or GA alone resulted in high rates of cell death in A549 and H460 cells. Treatment with GA and Admda7 combinations resulted in even greater enhancement of cell death in these cancer cells. Co-administration of Ad-mda7 and GA did not modify expression of MDA-7, nor was it associated with further PKR phosphorylation. In this study, we found that both Ad-mda7 and GA inhibit AKT expression in A549 and H460 cancer cells. GA also inhibits activation of AKT (p-AKT). To our surprise, however, we found that Ad-mda7 induces activation of AKT in both A549 and H460 lung cancer cells. It is clear that both apoptotic and survival (antiapoptotic) signals are present in Ad-mda7-treated cancer cells. The AKT-mediated survival-signaling pathway may play a role in resistance to adenovirus-mediated mda7 gene therapy. The serine/threonine kinase AKT is the cellular homologue of the retroviral oncogene product v-Akt. 19 A number of reports indicate that growth factors and cytokines stimulate cell survival. After stimulation with growth factors and cytokines, phosphatidylinositide-3-OH kinase is activated and phosphorylates phosphoinositides. The interaction of the generated phospholipid second messenger molecule, phosphatidylinositol 3,4,5-trisphosphate, with the pleckstrin homology domain of AKT recruits AKT to the plasma membrane, where it is phosphorylated at two key regulatory sites, residues Thr308 and Ser473. Activation of AKT in cancer cells leads to deregulation of growth and to desensitization of the tumor cell to proapoptotic stimuli. AKT regulates several transcription factors that control the expression of genes involved in the process (e.g. nuclear factor kappa B), and directly phosphorylates and inactivates components of the apoptotic machinery, including Bax, Bad and caspase 9. 20 Our results show that the combination of Ad-mda7 and GA inhibits AKT and p-AKT expression in both A549 and H460 human lung cancer cells. Inhibition of p-AKT by GA may be attributable in part to a synergistic effect of Ad-mda7 and GA. It also can be speculated that the enhancement of apoptotic effect induced by Ad-mda7 and GA involves one or more of the proteins evaluated (PKR, Raf-1 and AKT). Previous studies have demonstrated that Hsp90 inhibits activation of caspase-3 in vitro and in vivo. 21 In contrast to caspases-3, -6, -8 and -9, Hsp90 binds to Apaf-1 and blocks activation of procaspase-3. 22 To determine whether the combination of Ad-mda7 and GA dissociates the Hsp90-Apaf-1 complex and relieves inhibition of procaspase activation, further studies are needed. On the basis on the results presented, it is difficult to establish a specific causal relationship between the reduction in one of these proteins and the enhancement in Ad-mda7-mediated cytotoxicity. E-cadherin represents a family of membrane receptors that mediate calcium-dependent homophilic cell-cell adhesion. Disruption in expression or function of cadherins can result in uncontrolled cell migration and proliferation during tumor development. Treatment with the combination of Ad-mda7 and GA increased E-cadherin levels in both A549 and H460 cells. We also found that the Ad-mda7 and GA combination inhibited lung cancer cell motility, likely by increasing b-catenin/ E-cadherin association. Our results are consistent with the increased association of b-catenin and E-cadherin after GA treatment. 13 Further studies are need to determine whether the increased association of b-catenin and Ecadherin after Ad-mda7/GA combination treatment due to redistribution of E-cadherin and b-catenin. Previous findings indicate that E-cadherins can initiate outside-in signal transducing pathways that regulate the activity of PI 3-kinase and AKT. 23 By using Madin-Darby canine kidney cells as a model system, researcher showed that engagement of E-cadherins in homophylic calciumdependent cell-cell interactions results in a rapid PI 3-kinase-dependent activation of AKT and the subsequent translocation of AKT to the nucleus. 23 In our study, we found that Ad-mda7/GA combination treatment downregulate AKT and p-AKT proteins in A549 and H460 lung cancer cells.
b-Catenin is a multifunctional protein that plays an important role in both cell-cell interactions and transcriptional regulation. In normal epithelial cells, b-catenin associates with the cytoplasmic domain of E-cadherin, linking this transmembrane adhesion molecule to the actin cytoskeleton via hydrophobic association with a-catenin. 24 b-Catenin-E-cadherin association is critically important for the maintenance of tight cell-cell contacts.
GA derivative 17AAG showed good activity and cancer selectivity in preclinical models and has now progressed to aphase II clinical trial in cancer patients, with encouraging initial results. 25 Treatment with a combination of 17AAG and acute irradiation produces supra-additive growth suppression in human prostate carcinomas. 26 Addition of low doses of 17AAG enhanced the effects of paclitaxel and doxorubicin on HER2-overexpressing breast cancer cell lines. 27 As reported here, treatment with a combination of Ad-mda7 and the Hsp90 antagonist 17AAG resulted in enhancement of cell death in both A549 and H460 human lung cancer cells. Previous studies implicated 17AAG in disruption of the PI3K/AKT pathway in breast cancer cells, and downregulation of AKT has been associated with enhanced susceptibility of colon tumor cells to butyrate-induced apoptosis. 28 Such results raise the possibility that inactivation of AKT in human lung cancer cells exposed to Ad-mda7 and 17AAG may contribute to their synergistic effect. To determine whether the Ad-mda7 and 17AAG combination could regulate such targets, further studies are needed. Figure 4 17AAG enhances adenoviral mda-7-mediated cell killing in human lung cancer cells. Flow cytometric analysis of cell death in A549 and H460 cells after treatment with Ad-mda7, Ad-luc, 17AAG, Ad-mda7 plus 17AAG or Ad-luc plus 17AAG. Triplicate experiments were performed for each cell line.
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